Medical marijuana is one of the biggest healthcare stories out there right now.
We know that cannabis is a godsend for cancer patients, who use it to control their nausea and increase their appetite following chemotherapy.
Researchers are proving every day that cannabis-based drugs are effective against extreme pain, epilepsy, multiple sclerosis, and other ailments.
Plus, because of marijuana’s effectiveness in the fight against pain, everyone from doctors to law enforcement leaders are looking to use weed to help end the ongoing – and devastating – opioid crisis.
All that means medical marijuana is also one of the best investment opportunities out there.
That’s why I’ve recommended GW Pharmaceuticals PLC (Nasdaq ADR: GWPH) to you again and again.
But when it comes to medical marijuana, there’s a big problem.
Marijuana is probably the least studied cash crop in the world.
Researchers working to discover and refine the medicinal properties of cannabis have been greatly hampered by the Drug Enforcement Agency’s (DEA) classification of the plant as a Schedule 1 drug. That means the federal government deems marijuana as having no accepted medical use, like meth or heroin.
That stance has cut down on the sort of well-funded research that’s needed to usher in the next round of cannabis-based wonder drugs.
But that doesn’t mean no research is happening. After all, GW Pharma and other biotech firms have produced a first round of weed-based drugs.
In fact, there’s a small but growing cottage industry of tiny startups focused on the genetic testing of cannabis to help those biotechs
Some marijuana analytics startups, like Steep Hill, are developing their own gene-sequencing systems – and that’s something very exciting I plan to tell you more about soon.
But most, including Medicinal Genomics, are using state-of-the-art gene-sequencing equipment from the company I want to tell you about today.
This dynamic industry leader is a pioneer in the genetic testing equipment field. And now it’s equipment is crucial for medical marijuana pioneers.
If you got in when I first recommended this stock just a few months ago, you’ve already made nearly 19%.
But thanks to the medical marijuana sector’s interest and several more catalysts I’ll tell you about below, it’s got a lot further to run.
I had a terrible head cold – but the message got through.
No, it was more than a message…
It was a revelation.
It was back in June, and I was on the floor of the Fourth Annual Cannabis Business Summit & Expo in Oakland, California. My head was fuzzy due to the combo of viral infection and strong cold medicine, but I knew the conversation I was in was important.
I was talking to Chet Billings, CEO of legal cannabis investing company Mentor Capital Inc., and he was trying to explain the importance of compliance in his business. He was talking about cannabis companies’ need to follow all state and local business regulations – and to track their compliance.
Billings told me that we’re now approaching an era when mergers and acquisitions among marijuana companies are starting to happen. And buyers will only go after smaller firms of the highest quality. If they don’t have their compliance in order, he said, those acquirers will keep on trolling for more attractive fish.
The stakes are high, Billings said, and a lot of smaller operators simply don’t have experience with government regulation or the manpower to pay it the attention it needs without tech software to do the heavy lifting.
I must have still looked confused, because then he put it to me in a way that I, as a lifelong movie fan, could understand: “It’s like in the 1980s and ’90s when video rental shops still proliferated the landscape.”
Eventually, Billings recalled, Blockbuster came along and bought up the best video stores in each town. HollywoodVideo picked up the second-best ones. And the dustiest, most unfriendly places got left alone – and went out of business.
“Why would you want a ratty, local dispensary that resembles an old video store?” Billings said. “One false key stroke is a permanent violation. You get enough of those noncompliance violations – and you lose your license… and any chance at being a success.”
That’s one of the reasons why I’ve frequently recommended Microsoft Corp. (Nasdaq: MSFT) as a “starter” pot stock. The tech giant has made a big commitment to developing legal marijuana compliance software tools for governments and businesses.
And it’s really just one of the many “lessons” I’ve learned while out on the trail this year that I’ve used to make some of my members a mint through investing in the right marijuana stocks.
Now I’m using those same lessons to bring you these five pot stock predictions for 2018. All five are catalysts that will really drive the marijuana market upward in the next year.
Even after stacking up a bunch of double-, triple- and even quadruple-digit gains over the last year and a quarter, many of my Roadmap to Marijuana Millions pot stocks still have plenty of gas left.
In fact, a few of my Canadian legal marijuana plays in particular been on fire for months now – and especially since Nov. 10.
That’s the day Canada’s Department of Finance presented its cannabis tax plan on. The Canadian government plans to add a $1-per-gram excise tax on cannabis products, or 10% of the sale price, whichever is higher. Plus, the tax plan reiterated Canada’s commitment to legalize marijuana by July 2018.
No wonder my readers’ “Fast Fortune” Canadian pot stocks jumped higher.
One of those stocks rose 15% the day that news broke… another soared 10% that day… another jumped 6.8%… and another picked up13%.
But today we’re talking about the one that gained 15% on Nov. 10. We’re focusing on that one because it’s gone on to soar 76% since then thanks to another catalyst entirely. And it’s gained an amazing 766% since I first alerted my readers to it back in September 2016.
Today, I’ll tell you about that stock – and the “second” catalyst that boosted its gains.
Plus, I’ve identified another “trigger” that’s going to boost pot stocks on Jan. 1.
I want you to get in on these stocks before that catalyst hits.
The legal cannabis sector is no longer the “Wild West”-style marketplace it was back in, say, 2013, but there’s still plenty of volatility compared with the placid broader markets.
Then again, that’s why the right pot stocks reward forward-thinking investors with triple- and quadruple-digit gains. In fact, there’s a bevy of micro- and small-cap companies, any one of which could be the next mega-cap blockbuster – the long-sought-after “Starbucks of weed” or “Facebook of pot.”
My Nova-X Report’s Roadmap to Marijuana Millions model portfolio is chock-full of that kind of stocks. Right now my paid-up members are sitting on gains of 915%… 520.6%… 442.7%… and five more triple-digit winners. If you’d like to find out how to take advantage of this green revolution and get in on gains like those, click here.
But I don’t want to leave anyone with the impression that the only way to make a killing on pot stocks is to buy small, volatile companies. The gains from my Scotts Miracle-Gro Co. (NYSE: SMG) and GW Pharmaceuticals PLC (Nasdaq: GWPH) recommendations prove that just isn’t the case.
Then there’s the company I want to tell you about today.
It isn’t likely to quadruple your money quickly, but you’ll likely smash the market with double- and even triple-digit gains, and it pays a dividend that puts you way out ahead of inflation and low interest rates, too.
They may call it “weed,” but commercial legal cannabis – the “good stuff” – is more like a pampered, pedigreed dog.
Every pot grower knows that lots of care, technique, and technology goes into the cultivation and feeding of marijuana plants. All that’s needed so those plants can flower and produce commercially and medically useful compounds – especially the psychoactive tetrahydrocannabinol-9 (THC) that relieves pain and nausea and gets recreational users high.
This is seriously labor- and tech-intensive stuff. It’s also the specialty of the company I’m going to show you today.
Oakland, Calif. – Now that I’m on my way home from the Fourth Annual Cannabis Business Summit & Expo, there’s one statistic I just can’t stop thinking about.
And that’s a big deal.
You see, people throw around a ton of numbers at these conferences. But their true values can be incredibly opaque.
Whether the data you pick up on the Expo floor is from an entrepreneur, a lobbyist, a politician, an investment analyst, a researcher, a salesperson, or even a “brand representative,” you’ve got to do some work with it.
You’ve got to put it under the microscope, turn it around in your head, and figure out what it truly means. While most of the “tips” you get are just noise, many are interesting enough to share with friends.
But only a very, very few are truly valuable.
I’m talking about a number or statistic that flips a switch in your brain – and points your way toward future profits in your investment portfolio.
And the one number that stuck with me is this – 25%.
One of the great things about conferences – like the Marijuana Business Conference & Expo my team just attended – are the under-the-radar trends you pick up on.
The mainstream media is hardly talking about them. And the more specialized, niche coverage is busy with topics perceived as “bigger” – at least in the immediate term.
It’s the kind of valuable and credible information hanging out there on the fringes where millions are made.
And it’s why I’m personally attending the Cannabis Business Summit & Expo in Oakland, Calif., starting this upcoming Monday.
For example, at last month’s Marijuana Business Conference, a panel discussion on emerging legal marijuana markets may have flown under the radar with some inexperienced investors… but it jumped off the page to my team.
Panelist Michael Bronstein, of the law firm Bronstein & Weaver, proclaimed that New Jersey could become the most lucrative state recreational market east of the Rocky Mountains within two years. And he came equipped with plenty of data and anecdotes to back his claim up.
It makes sense.
First, New Jersey has a first-mover advantage, as none of its immediate neighbors will beat it to recreational legalization.
Plus, NJ borders two of five most populated cities in the country, New York and Philadelphia…it’s got a huge population all on its own… and it is home to communities hit hard by the decline of manufacturing looking for emerging industries like legal cannabis to bring in jobs and tax revenue.
In an effort to get tipped off on some similar profit-promising trends before I head to the Cannabis Business Summit, I spoke with a top executive of the group that sponsors that event.
I’ve repeatedly argued that legal marijuana – which will be a $24 billion industry by 2025 – is an unstoppable freight train, and that there’s hardly a thing Sessions can do about it. I’ve said it here – and to thousands of additional people who tuned in to my Pot Stock Summit last month.
I’ve come one step short of shouting it from the rooftops.
That’s no idle talk, either. As of right now, we’ve got 100% confirmation that Sessions has been totally beaten in his quest to roll back the pot prohibition clock to 1968.
Here’s how we got it: We went right into the “belly of the beast.”
When one of the largest marijuana business conferences in the country came to the Washington, D.C., area last month, my team jumped at the chance to head down I-95 to get the inside dirt.
We found that people in-the-know – politicians, former high-level government staffers, deep-pocketed investors, and even bankers – know that Sessions has already lost.
More importantly, my team talked directly with a fleet of A-list insiders who confirmed it. None was more calming than guy who literally wrote the book on federal marijuana guidance.